Eton Pharmaceuticals, Inc.
$25.28
▼
-1.46%
2026-04-21 06:43:00
www.etonpharma.com
NGM: ETON
Explore Eton Pharmaceuticals, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$683.2 M
Current Price
$25.28
52W High / Low
$27.29 / $13.09
Stock P/E
—
Book Value
$0.97
Dividend Yield
—
ROCE
-1.57%
ROE
-18.19%
Face Value
—
EPS
$-0.17
Exp Qtr EPS
—
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
44
Beta
0.97
Debt / Equity
118.85
Current Ratio
1.57
Quick Ratio
1.17
Forward P/E
16.9
Price / Sales
9
Enterprise Value
$724.36 M
EV / EBITDA
81.62
EV / Revenue
9.06
Rating
None
Target Price
$39.33
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Strong operating margin profile.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Bausch Health Companies Inc. | $5.91 | 14.05 | $3.02 B | — | 9.85% | 4.36% | $11.97 / $6.06 | $-1.5 |
| 2. | Amneal Pharmaceuticals, Inc. | $13.26 | 58.7 | $4.23 B | — | 14.23% | -80.04% | $15.42 / $7.01 | $-0.23 |
| 3. | Collegium Pharmaceutical, Inc. | $34.31 | 17.33 | $1.09 B | — | 14.67% | 23.7% | $50.79 / $25.86 | $9.51 |
| 4. | BioXcel Therapeutics, Inc. | $1.2 | — | $32.49 M | — | 557.9% | 74.14% | $8.08 / $1.01 | $-4.28 |
| 5. | Rockwell Medical, Inc. | $0.94 | — | $37.03 M | — | -9.86% | -15.28% | $2.1 / $0.78 | $0.94 |
| 6. | Cardiol Therapeutics Inc. | $1.51 | — | $230.46 M | — | -162.05% | -1.59% | $2.17 / $1.23 | $0.08 |
| 7. | BGM Group Ltd. | $0.36 | — | $59.42 M | — | -0.81% | -3.37% | $17.17 / $0.27 | $1.85 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 21.28 M | 22.46 M | 18.93 M | 17.28 M | 11.65 M | — |
| Operating Profit | 2.46 M | -1.36 M | -1.48 M | -0.47 M | 0.63 M | — |
| Net Profit | 1.48 M | -1.93 M | -2.58 M | -1.57 M | -0.6 M | — |
| EPS in Rs | 0.05 | -0.07 | -0.09 | -0.06 | -0.02 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 79.95 M | 39.01 M | 31.64 M | 21.25 M |
| Operating Profit | -0.84 M | -2.6 M | -1.19 M | -8.26 M |
| Net Profit | -4.6 M | -3.82 M | -0.94 M | -9.02 M |
| EPS in Rs | -0.17 | -0.14 | -0.03 | -0.33 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 92.11 M | 76.12 M | 31.74 M | 25.03 M |
| Total Liabilities | 65.96 M | 51.7 M | 16.26 M | 11.95 M |
| Equity | 26.15 M | 24.43 M | 15.48 M | 13.08 M |
| Current Assets | 60.58 M | 41.02 M | 26.84 M | 20 M |
| Current Liabilities | 38.49 M | 19.95 M | 16.24 M | 6.46 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 10.52 M | 0.97 M | 6.82 M | 4.82 M |
| Investing CF | -0.33 M | -40.01 M | -0.78 M | -2.79 M |
| Financing CF | 0.81 M | 32.59 M | -0.96 M | -0.13 M |
| Free CF | 10.19 M | -9.04 M | 6.04 M | 2.03 M |
| Capex | -0.33 M | -10.01 M | -0.78 M | -2.79 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 23.29% | 48.9% | — | — |
| Earnings Growth % | -308.44% | 89.62% | — | — |
| Profit Margin % | -9.8% | -2.96% | -42.45% | — |
| Operating Margin % | -6.66% | -3.77% | -38.87% | — |
| Gross Margin % | 60.01% | 66.56% | 67.38% | — |
| EBITDA Margin % | -3.72% | -0.92% | -30.52% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.